1,979 research outputs found
PATHOLOGICAL CHANGES IN SIX TREATED BABOON‐TO‐MAN RENAL HETEROTRANSPLANTS
Six baboon‐to‐man renal heterotransplants, each consisting of a pair of kidneys, were examined. Two had been removed from their recipients at forty‐nine and sixty days after transplantation because of the ever‐increasing doses of immunosuppressive drugs needed to control rejection; the other four pairs of kidneys were examined after death of the recipients at nineteen, twenty‐three, thirty‐five, and forty‐nine days. All the kidneys were enlarged. On the subcapsular surfaces of one pair there were petechias; four were mottled with irregular haemorrhages and infarcts; one pair had undergone almost complete hemorrhagic infarction. The transplants were heavily infiltrated with plasma cells, lymphocytes, large pyroninophilic lymphoid cells and eosinophils. Mitoses, “LE” cells and erythrophagocytosis were seen. Associated with this infiltration there was rupture of peritubular capillaries, interstitial cedema and widespread tubular damage. Fibrinoid necrosis of the walls of arterioles and interlobular arteries, with narrowing and obstruction of some vessels by fibrin and platelet deposits on the intima were common in all except one pair of kidneys. Associated with these vascular lesions there were focal infarcts and extensive interstitial haemorrhages. All the histological changes were more severe than those seen either in treated human renal homotransplants or in a comparable series of chimpanzee‐to‐man renal heterotransplants where cellular infiltration was slight and vascular lesions only present at the height of rejection. This work was aided by grants A‐6283, A‐6344, HE‐07735, AM‐07772, A1‐01452, and OG‐27 from the U.S. Public Health Service, and by a grant from the Medical Research Council. We would like to thank Drs D. Baitlon, J. Gordon, R. B. Hill, D. Lang, and D. E. Smith who performed the autopsies on these cases. We are particularly grateful to Dr D. T. Rowlands, who supervised most of the autopsies, for his helpful co‐operation throughout this study. Expert assistance in preparing the sections and photomicrographs was given by Miss Jane Rendall. © 1965 BJU International Compan
Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Kidney Transplantation: A Multi-Institution Study in Japan Over 30 years
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). With increasing alternative donors available, the preferred donor or stem cell source is debated. We set out to study outcome in recipients of alloHSCT with poor-risk AML in first complete remission (CR1) by donor type. A total of 6545 adult patients with poor-risk AML in CR1 receiving an alloHSCT using matched related donor (MRD, n = 3511) or alternative donors, including 10/10 (n = 1959) or 9/10 matched unrelated donors (MUDs, n = 549), umbilical cord blood (UCB) grafts (n = 333), or haplo-identical (haplo) donors (n = 193) were compared. Overall survival (OS) at 2 years following MRD alloHSCT was an estimated 59 +/- 1%, which did not differ from 10/10 MUD (57 +/- 1%) and haplo alloHSCT (57 +/- 4%). OS, however, was significantly lower for 9/10 MUD alloHSCT (49 +/- 2%) and UCB grafts (44 +/- 3%), respectively (P < .001). Nonrelapse mortality (NRM) depended on donor type and was estimated at 26 +/- 3% and 29 +/- 3% after haplo alloHSCT and UCB grafts at 2 years vs 15 +/- 1% following MRD alloHSCT. Multivariable analysis confirmed the impact of donor type with OS following MRD, 10/10 MUD, and haplo alloHSCT not being statistically significantly different. NRM was significantly higher for alternative donors as compared with MRD alloHSCT. Collectively, these results suggest that alloHSCT with MRDs and 10/10 MUDs may still be preferred in patients with poor-risk AML in CR1. If an MRD or 10/10 MUD is not available, then the repertoire of alternative donors includes 9/10 MUD, UCB grafts, and haplo-identical donors. The latter type of donor is increasingly applied and now approximates results with matched donors.Peer reviewe
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.
The aim of supportive autografting is to reduce the side effects from stem cell transplantation and avoid procedure-related health disadvantages for patients at the lowest possible cost and resource expenditure. Economic evaluation of health care is becoming increasingly important. We report clinical and laboratory data collected from 397 consecutive adult patients (173 non-Hodgkin lymphoma, 30 Hodgkin lymphoma, 160 multiple myeloma, 7 autoimmune diseases, and 28 acute leukemia) who underwent their first autologous peripheral blood stem cell transplantation (PBSCT). We considered primary endpoints evaluating health economic efficacy (eg, antibiotic administration, transfusion of blood components, and time in hospital), secondary endpoints evaluating toxicity (in accordance with Common Toxicity Criteria), and tertiary endpoints evaluating safety (ie, the risk of regimen-related death or disease progression within the first year after PBSCT). A time-dependent grading of efficacy is proposed with day 21 for multiple myeloma and day 25 for the other disease categories (depending on the length of the conditioning regimen) as the acceptable maximum time in hospital, which together with antibiotics, antifungal, or transfusion therapy delineates four groups: favorable (≤7 days on antibiotics and no transfusions; ≤21 [25] days in hospital), intermediate (from 7 to 10 days on antibiotics and 7 days on antibiotics, >3 but 30/34 days in hospital after transplantation), and very unfavorable (>10 days on antibiotics, >6 transfusions; >30 to 34 days in hospital). The multivariate analysis showed that (1) PBSC harvests of ≥4 × 106/kg CD34 + cells in 1 apheresis procedure were associated with a favorable outcome in all patient categories except acute myelogenous leukemia and acute lymphoblastic leukemia (P = .001), (2) ≥5 × 106/kg CD34 + cells infused predicted better transplantation outcome in all patient categories (P 500 mL) (P = .002), and (5) patients with a central venous catheter during both collection and infusion of PBSC had a more favorable outcome post-PBSCT than peripheral access (P = .007). The type of mobilization regimen did not affect the outcome of auto-PBSCT. The present study identified predictive variables, which may be useful in future individual pretransplantation probability evaluations with the goal to improve supportive care
Setting up and sustaining blood and marrow transplant services for children in middle-income economies : an experience-driven position paper on behalf of the EBMT PDWP
Publisher Copyright: © 2020, The Author(s).Severe blood disorders and cancer are the leading cause of death and disability from noncommunicable diseases in the global pediatric population and a major financial burden. The most frequent of these conditions, namely sickle cell disease and severe thalassemia, are highly curable by blood or bone marrow transplantation (BMT) which can restore a normal health-related quality of life and be cost-effective. This position paper summarizes critical issues in extending global access to BMT based on ground experience in the start-up of several BMT units in middle-income countries (MICs) across South-East Asia and the Middle East where close to 700 allogeneic BMTs have been performed over a 10-year period. Basic requirements in terms of support systems, equipment, and consumables are summarized keeping in mind WHO’s model essential lists and recommendations. BMT unit setup and maintenance costs are summarized as well as those per transplant. Low-risk BMT is feasible and safe in MICs with outcomes comparable to high-income countries but at a fraction of the cost. This report might be of assistance to health care institutions in MICs interested in developing hematopoietic stem cell transplantation services and strengthening context appropriate tertiary care and higher medical education.Peer reviewe
Kidney transplant outcomes from older deceased donors : a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry
As the median age of deceased kidney donors rises, updated knowledge of transplant outcomes from older deceased donors in differing donor-recipient age groups is required. Using ERA-EDTA Registry data we determined survival outcomes of kidney allografts donated from the same older deceased donor (55-70 years), and transplanted into one recipient younger and one recipient of similar age to the donor. The recipient pairs were divided into two groups: group 1; younger (median age: 52 years) and older (60 years) and group 2; younger (41 years) and older (60 years). A total of 1410 adults were transplanted during 2000-2007. Compared to the older recipients, the mean number of functioning graft years at 10 years was 6 months longer in the group 1 and group 2 younger recipients (P <0.001). Ten-year graft survival was 54% and 40% for the group 1 younger and older recipients, and 60% and 49% for the group 2 younger and older recipients. Paired Cox regression analyses showed a lower risk of graft failure (group 1 younger; adjusted relative risk [RRa]:0.57, 95% CI:0.41-0.79, and group 2 younger; RRa:0.63, 95% CI:0.47-0.85) in younger recipients. Outcomes from older deceased donor allografts transplanted into differing donor-recipient age groups are better than previously reported. These allografts remain a valuable transplant resource, particularly for similar-aged recipients.Peer reviewe
P neumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/89470/1/tid692.pd
Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms
With accumulating evidence and improved outcomes along with recognition that modern biological therapies are not universally effective, require chronic administration and have high acquisition costs, hematopoietic stem cell transplantation (HSCT) has become an emerging direction for cell therapy in autoimmune diseases (ADs). The goal of this therapy is to induce medication-free remissions by resetting the immune system into a naïve and self-tolerant state through eradication of the autoreactive immunologic memory and profound re-configuration of the immune system induced by the transplant procedure. Safety of HSCT has generally improved by implementing internal quality management and external accreditation. Inter-disciplinary guidelines for patient selection, transplant technique and supportive care along with greater center experience should optimize safe and appropriate delivery of HSCT in specific ADs. In this review, we discuss the current role and future perspectives of HSCT in AD, focusing on recent published clinical and scientific studies and recommendations in the field
- …